December 11, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) today announced the publication of positive data from a pre-clinical study demonstrating the safety and efficacy to treat pain directly with a topical version of AdvilTM (ibuprofen) and CelebrexTM (celecoxib). Testing for effects on joint pain and inflammation; topical Delivra-ibuprofen and Delivra-celecoxib formulations offer sustained long-term pain and swelling reduction, compared to oral equivalents. These results were published in the respected peer-reviewed scientific journal, Journal of Pain Research, under the title, “Penetration and efficacy of transdermal NSAIDs in a model of acute joint inflammation”. The article may be found at the following link:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239099/?report=reader

In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen and Delivra-celecoxib formulations provided sustained pain reduction. In the study, both Delivra formulations were tested in an acute dog model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls. This exemplifies Delivra’s technology, with its multi-laminar system, is capable of gradually releasing the active ingredient to the area of need. This transdermal, designed “slow release” is a valuable and highly advantageous characteristic of the topical Delivra-ibuprofen and Delivra-celecoxib creams and may offer significant advantages over oral medication. These formulations will provide better localization of the drug at the site of need, yielding quicker and longer lasting relief.

“This impressive data further validates Delivra’s platform technology by outperforming oral delivery and offering patients an effective, safe and convenient cream for pain management. Our robust pharmaceutical pipeline of high-value innovative products, including Delivra-ibuprofen and Delivra-celecoxib formulations, provide an array of unique commercialization opportunities. As such, we will continue to pursue out-licensing opportunities for major global markets to unlock the value of our portfolio,” said Dr. Joseph Gabriele, CEO of Delivra.

For these two formulations, the Company has two PCT patent pending applications.

ABOUT DELIVRA CORP.

Delivra Corp. is a specialty biotechnology company having a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin, in a targeted manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and sports performance. LivReliefTM products are available in over 6,000 retail locations, including pharmacies, grocery chains, and independent health food stores across Canada, including, but not limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London Drugs, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending, proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Hamilton, Ontario and has a research and development laboratory in Charlottetown, PEI.

Further information on Delivra can be found at www.delivracorp.com and www.livrelief.com.

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute “forward-looking statements”, which are not comprised of historical facts. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “intends”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”, and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the Company’s revenues and financial performance; the Company’s drug research and development plans; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Delivra to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management’s expectations. In formulating the forward-looking statements contained herein, management has assumed that business and economic conditions affecting Delivra will continue substantially in the ordinary course and will be favourable to Delivra; that the Company will continue to complete orders with existing customers and control product pricing and expenses that clinical testing results will justify commercialization of the Company’s drug candidates; that Delivra will be able to obtain all requisite regulatory approvals to commercialize its drug candidates, that such approvals will be received on a timely basis, and that Delivra will be able to find suitable partners for development and commercialization of its products and intellectual property on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect. Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: the ability of the Company to maintain existing product sales with current customers at existing product pricing and expenses; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the ability of the Company to generate sales and profits; the Company’s ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Delivra’s public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Delivra disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Dr. Joseph Gabriele

Chief Executive Officer

info@delivracorp.com

905-561-5014